Prognostic Factors for Overall Survival in Patients With Metastatic Colorectal Carcinoma Treated With Vascular Endothelial Growth Factor-Targeting Agents

Cetin, Bulent; Kaplan, Mehmet Ali; Berk, Veli; Ozturk, Selcuk Cemil; Benekli, Mustafa; Isikdogan, Abdurrahman; Ozkan, Metin; Coskun, Ugur; Buyukberber, Suleyman

추천

검색

자료유형: 학술저널

저자정보: Cetin, Bulent (Department of internal Medicine, Gazi University Faculty of Medicine) Kaplan, Mehmet Ali (Department of internal Medicine, Dicle University Faculty of Medicine) Berk, Veli (Department of internal Medicine, Division of Medical Oncology, Erciyes University Faculty of Medicine) Ozturk, Selcuk Cemil (Department of internal Medicine, Dicle University Faculty of Medicine) Benekli, Mustafa (Department of internal Medicine, Gazi University Faculty of Medicine) Isikdogan, Abdurrahman (Department of internal Medicine, Dicle University Faculty of Medicine) Ozkan, Metin (Department of internal Medicine, Division of Medical Oncology, Erciyes University Faculty of Medicine) Coskun, Ugur (Department of internal Medicine, Gazi University Faculty of Medicine) Buyukberber, Suleyman (Department of internal Medicine, Gazi University Faculty of Medicine)

저널정보: 아시아태평양암예방학회 Asian Pacific journal of cancer prevention : APJCP Asian Pacific journal of cancer prevention : APJCP 제13권 제3호

발행연도: 2012.1

수록면: 1,059 - 1,063 (5page)

이용수

📌

연구주제

📖

연구배경

🔬

연구방법

🏆

연구결과

초록· 키워드

오류제보하기

Objective: Angiogenesis represents a key element in the pathogenesis of malignancy. There are no robust data on prognostic factors for overall survival (OS) in patients with metastatic colorectal cancer treated with vascular endothelial growth factor (VEGF)-targeted therapy. The present study was conducted to establish a prognostic model for patients using an oxaliplatin-based or irinotecan-based chemotherapy plus bevacizumab in metastatic colorectal cancer. Methods: Baseline characteristics and outcomes on 170 patients treated with FOLFIRI or XELOX plus anti-VEGF therapy-naive metastatic colorectal cancer were collected from three Turkey cancer centers. Cox proportional hazards regression was used to identify independent prognostic factors for OS. Results: The median OS for the whole cohort was 19 months (95% CI, 14.3 to 23.6 months). Three of the seven adverse prognostic factors according to the Anatolian Society of Medical Oncology (ASMO) were independent predictors of short survival: serum lactate dehydrogenase (LDH) greater than the upper limit of normal (ULN; p<0.001); neutrophils greater than the ULN (p<0.0014); and progression free survival (PFS) less than 6 months (p =0.001). Conclusion: Serum LDH and neutrophil levels were the main prognostic factors in predicting survival, followed by PFS. This model validates incorporation of components of the ASMO model into patient care and clinical trials that use VEGF-targeting agents.

#Vascular endothelial growth factor #bevacizumab #prognostic factors #metastatic colorectal cancer

참고문헌 (0)

참고문헌 신청

참고문헌이 DBpia에서 서비스 중이라면, [참고문헌 신청]을 통해 등록해보세요